Phaseline

Targets › CCR2

CCR2 (C-C chemokine receptor type 2): drug programs, companies and trials

4 programs from 4 companies in 5 trials: 3 Phase 2, 1 Phase 3, 1 Phase 1; Oncology, Genitourinary, Cardiovascular; next expected readout Jul 2028.

Key functional receptor for CCL2 but can also bind CCL7, and CCL12. Also transduces signaling mediated by CCL13. (UniProt, P41597)

Open in Phaseline: the race on CCR2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Dimerix BioscienceDMX-200 (repagermanium)
C-C chemokine receptor type 2 (CCR2) inhibitor
CCR2Phase 3FSGSDec 2029
Icahn School of Medicine at Mount SinaiBMS-813160
C-C chemokine receptor type 2 antagonist; C-C chemokine receptor type 5 antagonist
CCR2, CCR5Phase 2Non-small Cell Lung CancerJul 2028
QuantumLeap Healthcare CollaborativeCenicriviroc
C-C chemokine receptor type 5 antagonist; C-C chemokine receptor type 2 antagonist
CCR5, CCR2Phase 2COVID-19Jul 2028
Washington University School of Medicine64CU-DOTA-ECL1i
CCR2-targeting radiotracer for PET imaging
CCR2Phase 2Head and Neck Squamous Cell Carcinoma; Carotid AtherosclerosisMay 2032

Conditions

FSGS (1) Head and Neck Squamous Cell Carcinoma (1) Carotid Atherosclerosis (1) Non-small Cell Lung Cancer (1) COVID-19 (1)

Modalities

small molecule (2), mixed (2)

Companies

Dimerix Bioscience (1) Washington University School of Medicine (1) Icahn School of Medicine at Mount Sinai (1) QuantumLeap Healthcare Collaborative (1)

Related targets

CCR5 (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.